Allogene Therapeutics Inc (ALLO) Company Profile & Statistics

Allogene Therapeutics Inc
ALLO
(Nasdaq - US)
Closed
3.46
-0.05 (-1.43%)
in:usd•As of: Apr 18, 2024 15:59 UTC -4
Open
3.50
High
3.56
Low
3.46

About Allogene Therapeutics Inc

CEO

David Chang

Headquarters

210 east grand avenue

south san francisco, ca 94080, united states

Auditor

Ernst & Young LLP

Employees

233

Share Holders

Website

www.allogene.com

Industry

biotechnology

Sector

health technology

Company Overview

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company, primarily focused on the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer.?

Allogene Therapeutics Inc Statistics

Valuation Measures

Market Capitalization ²	585.05M
Enterprise Value	501.90M
Enterprise Value/EBITDA (ttm)	-1.57
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	1.15
Price to Sales (ttm)	3.70K
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	100.00%
Operating Margin (ttm)	-194088.09%
Profit Margin (ttm)	-76699.83%
Return on Equity (ttm)	-53.76%
Return on Invested Capital (ttm)	-57.13%
Return on Assets (ttm)	-43.24%

Income Statement

Revenue (ttm)	95.00K
Revenue Per Share (ttm)	0.00
Gross Profit (ttm)	95.00K
EBITDA (ttm)³	-320.35M
Net Income Avi to Common (ttm)	-327.26M
Diluted EPS (ttm)	-2.09

Share Statistics

Beta (5Y Monthly)	0.81
52-Week Change	-27.92%
S&P500 52-Week Change	20.61%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	169.09M
Dividend Yield	0.00%
Float ⁴	122.76M
% Held by Insiders	27.40%
% Held by Institutions	83.63%

Balance Sheet

Total Cash (mrq)	448.70M
Total Cash Per Share (mrq)	2.65
Total Debt (mrq)	0.00
Total Debt/Equity (mrq)	0.00%
Current Ratio (mrq)	12.38%
Quick Ratio (mrq)	12.38%
Book Value Per Share (mrq)	3.04

Cash Flow

Operating Cash Flow Per Share (ytd)	-1.51
Free Cash Flow (ytd)	-239.25M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Allogene Therapeutics Inc

Trade With A Regulated Broker